---
figid: PMC8197596__13195_2021_858_Fig1_HTML
figtitle: 'Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?'
organisms:
- NA
pmcid: PMC8197596
filename: 13195_2021_858_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8197596/figure/Fig1/
number: F1
caption: 'Possible mechanisms of APOE4-mediated AD and COVID-19 comorbidity. Left
  panel: A ten-member network shared by both AD (all members) and COVID-19 (*), generated
  by using MetaCore. In the case of APOE4, reduced/altered APOE has three potential
  actions in this network alone: (1) disinhibition of ACE2, (2) transcriptional reduction
  of the protective LZTFL1, and (3) more indirect disinhibition of NRP1 via LZTF1,
  in exacerbation of COVID-19. Asterisks are for genetic association with severe COVID-19:
  APOE: rs429358 (APOE2/3 vs 4) p = 0.0026, OR = 1.31; ACE2: chr23:15564667 p = 0.0056,
  OR = 1.12; CTNNB1: chr3:41204313 p = 0.016, OR = 0.74; LZTFL1: chr3:45834967 p =
  1.15 × 10−10, OR = 0.56; NOTCH1: chr9:136510909 p = 0.0092, OR = 0.87; MMP1: rs11621460
  p = 0.010, OR = 0.84; NRP1: chr10:33292184 p = 0.00072, OR = 1.47; RelA: rs1049728
  p = 0.0063, OR = 0.64 (II); SIRT1: rs12783242 p = 0.0019, OR = 0.78; where chromosome
  positions are based on HG38 in the absence of rs numbers; OR, odds ratio; II, adjusted
  with gender and age; all association signals are provided by the GWAS meta-analysis
  by Ellinghaus et al. Not shown here is the additional APOE-LRP1-PARP1-TMPRSS2 pathway
  (see text): LRP1: rs4759044 p = 0.023, OR = 0.89; PARP1: chr1:226405149 p = 0.0065,
  OR = 0.51 (II). Right panel: APOE4-based vulnerability for patients with COVID-19
  and AD at double risk: attenuated protective behavior for exposure risk and APOE4-associated
  infection risk'
papertitle: 'Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?.'
reftext: Nian Xiong, et al. Alzheimers Res Ther. 2021;13:111.
year: '2021'
doi: 10.1186/s13195-021-00858-9
journal_title: Alzheimer's Research & Therapy
journal_nlm_ta: Alzheimers Res Ther
publisher_name: BioMed Central
keywords: APOE4 | Biomarker | Coronavirus | Comorbidity | Peripheral mechanisms |
  COVID-19
automl_pathway: 0.8991334
figid_alias: PMC8197596__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8197596__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8197596__13195_2021_858_Fig1_HTML.html
  '@type': Dataset
  description: 'Possible mechanisms of APOE4-mediated AD and COVID-19 comorbidity.
    Left panel: A ten-member network shared by both AD (all members) and COVID-19
    (*), generated by using MetaCore. In the case of APOE4, reduced/altered APOE has
    three potential actions in this network alone: (1) disinhibition of ACE2, (2)
    transcriptional reduction of the protective LZTFL1, and (3) more indirect disinhibition
    of NRP1 via LZTF1, in exacerbation of COVID-19. Asterisks are for genetic association
    with severe COVID-19: APOE: rs429358 (APOE2/3 vs 4) p = 0.0026, OR = 1.31; ACE2:
    chr23:15564667 p = 0.0056, OR = 1.12; CTNNB1: chr3:41204313 p = 0.016, OR = 0.74;
    LZTFL1: chr3:45834967 p = 1.15 × 10−10, OR = 0.56; NOTCH1: chr9:136510909 p =
    0.0092, OR = 0.87; MMP1: rs11621460 p = 0.010, OR = 0.84; NRP1: chr10:33292184
    p = 0.00072, OR = 1.47; RelA: rs1049728 p = 0.0063, OR = 0.64 (II); SIRT1: rs12783242
    p = 0.0019, OR = 0.78; where chromosome positions are based on HG38 in the absence
    of rs numbers; OR, odds ratio; II, adjusted with gender and age; all association
    signals are provided by the GWAS meta-analysis by Ellinghaus et al. Not shown
    here is the additional APOE-LRP1-PARP1-TMPRSS2 pathway (see text): LRP1: rs4759044
    p = 0.023, OR = 0.89; PARP1: chr1:226405149 p = 0.0065, OR = 0.51 (II). Right
    panel: APOE4-based vulnerability for patients with COVID-19 and AD at double risk:
    attenuated protective behavior for exposure risk and APOE4-associated infection
    risk'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CXCL8
  - NAP1L1
  - NAPSA
  - ACOT8
  - NCKAP1
  - TRMO
  - AZI2
  - NAA25
  - TAB3
  - RELA
  - MMP14
  - CTNNB1
  - LZTFL1
  - APOE
  - MMP1
  - SIRT1
  - NOTCH1
  - ACE2
  - ERVK-8
  - ERVK-10
  - ERVK-9
  - ERVK-21
  - ERVK-18
  - ERVK-25
  - ERVK-24
  - ERVK-19
---
